Abstract: The present disclosure provides methods for colorizing and/or standardizing a medical image, comprising, for example, the steps of (i) receiving, in an image processing unit, digital image data obtained by an image capture device, wherein the digital image data includes a medical image; (ii) analyzing the data with the image processing unit to identify a region of interest; (iii) segmenting said region of interest; (iv) obtaining a measure of the pixel intensities in the segmented region of interest; (v) selecting an optimized color spectrum from a plurality of color spectra using the result of the measure of the pixel intensities in the segmented region of interest; (vi) colorizing the digital image data by mapping the selected color spectrum to the region of interest; and (vii) displaying the colorized medical image.

Abstract: A method for localizing and quantifying S1R role in nociceptive processing; for providing a guide to providing an analgesic therapy; of using an S1R selective ligand as a biomarker for pathphysiological study of memory deficits and cognitive disorders; or of detecting increased S1R density at the site of nerve injury arising from neuropathic pain comprising using as a probe at least one SR1 selective compound or radioligand of the general formula III?, or IV?:

Abstract: A compound including a cell penetrating peptide (CPP) and elastin-like polypeptide (ELP), and a method for use thereof, are useful for inhibiting the proliferation of cancer.

Abstract: Suppository, hot melt and ophthalmic formulations containing amino esters of the formulae (I), (II) and (III), where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof.

Abstract: Compounds having the general formula III?, or IV? wherein R1 can be a radical of an optionally substituted C-4 to C-7 N-containing heterocycle or a radical of an optionally substituted cyclic or acyclic tertiary amine or isoindoline-1,3-dione: R2,4,5,6 can each independently be any one or combinations of the following moieties, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate, optionally substituted anilino, halogens, ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylene, deuterium, or tritium; Y is S; Z can be either H, O, S, S—R or NR where R groups can be either H, aryls, alkyls, or cycloalkyls; “n” can be 1 to 5 carbons in length and stereoisomers, functional analogs, and pharmaceutically acceptable salts thereof and wherein the moiety bridging R1 and N can be a substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene and where the alkylene group can include an inserted C3-C5 cycloalkyl group, aromatic, and heterocycli

Abstract: We report for the first time that pterostilbene, a natural analog of resveratrol, shows anxiolytic-like action by downregulating phosphorylated levels of ERKs in the hippocampus of mice. Mice administered pterostilbene (1-10 mg/kg BW) by oral gavage were subjected to the Elevated-plus maze (EPM) test. Pterostilbene manifested anxiolytic activity at 1 and 2 mg/kg doses, demonstrated by an increase in percent permanence time and number of entries in open arms, critical determinants correlated with anxiety. This anxiolytic activity of pterostilbene was comparable to that of diazepam at 1 and 2 mg/kg in the EPM. The percent traveled distance and the percent permanence time in the enclosed arms were decreased with the 1 and 2 mg/kg doses. The 5 and 10 mg/kg doses did not show any anxiolytic effect. Locomotor activity was unaffected in all doses.

Abstract: The present invention, in one or more embodiments, comprises water-soluble derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecylcatechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising water soluble urushiol esters of general formula (I) tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a composition containing at least one water soluble urushiol ester compound.

Abstract: The present disclosure relates to peptides for treating cancer, wherein the peptides suppress BRCA1-IRIS expression or activity. The peptides may include an amino acid sequence as set forth in SEQ ID NO: 1 and/or SEQ ID NO: 2. Further, the present disclosure provides methods for treating cancer, wherein the cancer may be breast or ovarian cancer, including administering one of said peptides to a subject in need thereof.

Abstract: A method and device is disclosed for reducing and controlling stuttering. The method involves tactile feedback of the stutterer's own speech to reducing stuttering. In one embodiment, the device may detect speech by audible or mechanical means, and the feedback may be produced by vibration mechanisms.

Abstract: The present invention relates to compounds of the formulae: in which R is C5-C16 alkyl, R1 is and isosteres and salts thereof.

Abstract: The present disclosure relates to peptides for treating cancer, wherein the peptides suppress BRCA1-IRIS expression or activity. The peptides may include an amino acid sequence as set forth in SEQ ID NO: 1 and/or SEQ ID NO: 2. Further, the present disclosure provides methods for treating cancer, wherein the cancer may be breast or ovarian cancer, including administering one of said peptides to a subject in need thereof.

Abstract: We report the synthesis and characterization of four novel CCC—NHC pincer platinum(II) and palladium(II) complexes, which adopt a distorted square planar configuration. These complexes emit bright blue light in the solid state under UV irradiation with emissions that are stable in ambient atmosphere (O2 and H2O) for extended periods. We also report the synthesis and characterization of CCC—NHC pincer ligand nickel complexes, and solid state fluorescence spectra have been collected for two of the complexes reported. X-ray structural analysis of a representative compound exhibits a distorted square planar geometry. Finally, we report the synthesis and characterization of CCC—NHC pincer ligand complexes for abnormal carbenes, triazole, and BIA.

Abstract: Methods for diagnosis and treatment of a cancer treatable with a c-Abl inhibitor are provided. Methods for diagnosing a cancer treatable with a c-Abl inhibitor include providing a biological sample from subject, determining an amount in the sample of geminin, c-Abl, or both, and comparing the amount of geminin, c-Abl, or both, if present, to a control level to thereby diagnose a subject as having a cancer treatable with a c-Abl inhibitor if there is a measurable difference in the amount of geminin, c-Abl, or both in the sample as compared to the control level. Methods for treating a cancer include identifying a subject as having a cancer treatable with a c-Abl inhibitor by determining an amount of geminin, c-Abl, or both, and then administering an effective amount of a c-Abl inhibitor to the subject. Screening methods for identifying compounds useful for inhibiting c-Abl are also provided.

Abstract: A two-scale array for detecting wind noise signals and acoustic signals includes a plurality of subarrays each including a plurality of microphones. The subarrays are spaced apart from one another such that the subarrays are configured to detect acoustic signals, and the plurality of microphones in each subarray are located close enough to one another such that wind noise signals are substantially correlated between the microphones in each subarray.

Abstract: We report the synthesis and characterization of four novel CCC-NHC pincer platinum(II) and palladium(II) complexes, which adopt a distorted square planar configuration. These complexes emit bright blue light in the solid state under UV irradiation with emissions that are stable in ambient atmosphere (O2 and H2O) for extended periods. We also report the synthesis and characterization of CCC-NHC pincer ligand nickel complexes, and solid state fluorescence spectra have been collected for two of the complexes reported. X-ray structural analysis of a representative compound exhibits a distorted square planar geometry. Finally, we report the synthesis and characterization of CCC-NHC pincer ligand complexes for abnormal carbenes, triazole, and BIA.

Abstract: The present invention, in one or more embodiments, comprises water-soluble derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecylcatechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising water soluble urushiol esters of general formula (I) Tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a composition containing at least one water soluble urushiol ester compound.

Abstract: This invention relates generally to animal models of anxiety and depression. Specifically, this invention relates to an in vivo high utility, high-throughput model for screening anxiolytic/antidepressant drugs in fowl chicks with stress vulnerability. This new animal model utilizes an inexpensive avian model, measures spontaneous behaviors in very young animals, and is capable of detecting and/or differentiating a compound's anxiolytic and/or antidepressant effects. This new animal model is especially useful in detecting and/or differentiating a compound's anxiolytic and/or antidepressant effects in treatment-resistant subjects. Animal costs are less than 10% of rodent costs and the assay can be run in a high-throughput mode.

Abstract: Aspects of the present invention include methods for inhibiting damage to a mammalian cornea, comprising administering an effective ?-toxin inhibiting about of a composition that comprises a ?-cyclodextrin and cholesterol.

Abstract: Embodiments of the presently-disclosed subject matter include methods and systems for measuring a level of a neurotransmitter in a subject. Embodiments of the present methods comprise displaying a fixation point, a reward target, and a non-reward target, and measuring one or more saccade movement parameters for reward saccades and non-reward saccades. The saccade movement parameters can include velocity, amplitude, reaction time, or a combination thereof. The present methods can further include determining a reward modulation of the subject, the reward modulation being equal to a difference between the reward and the non-reward values for a respective saccade movement parameter. Some embodiments further include identifying the subject as including a deficiency of the neurotransmitter if there is a statistically measurable difference between the reward modulation of the subject and a reference reward modulation and/or if the non-reward and the reward saccade movement parameters are statistically equivalent.

Abstract: A diagnostic method and predictor of prognosis from various therapeutic treatments is provided using discriminant analysis statistics. In one form, a patient is identified as having a disease using discriminant analysis when one or more values of a physiological parameter of the patient is closer to that of a previously characterized group of individuals having a disease and the patient is diagnosed as not having the disease, or healthy, if the value of a patient's parameter is closer to that of individuals previously characterized as healthy, or not having the disease. For example, the parameters can be based on the autonomic and/or enteric nervous system. Advantageously, the present method can be readily adapted using conventional linear discriminant analysis statistics to factor more than one parameter between a patient and one or more previously classified groups, to thereby enhance predictability and reliability of the present method.